يعرض 1 - 10 نتائج من 10 نتيجة بحث عن '"Mamidi, Rao N. V. S."', وقت الاستعلام: 0.87s تنقيح النتائج
  1. 1
    دورية أكاديمية
    In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin.

    المؤلفون: Mamidi, Rao N. V. S.1 smamidi1@its.jnj.com, Dallas, Shannon2, Sensenhauser, Carlo2, Lim, Heng Keang2, Scheers, Ellen3, Verboven, Peter3, Cuyckens, Filip3, Leclercq, Laurent3, Evans, David C.2, Kelley, Michael F.2, Johnson, Mark D.1, Snoeys, Jan3

    المصدر: British Journal of Clinical Pharmacology. May2017, Vol. 83 Issue 5, p1082-1096. 15p. 9 Charts, 6 Graphs, 1 Map.

    مصطلحات موضوعية: *DRUG interactions, *DRUG side effects, *TYPE 2 diabetes treatment, *TREATMENT of diabetes, *CYTOCHROME P-450

    النص الكامل

    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    In vitro metabolism of canagliflozin in human liver, kidney, intestine microsomes, and recombinant uridine diphosphate glucuronosyltransferases (UGT) and the effect of genetic variability of UGT enzymes on the pharmacokinetics of canagliflozin in humans.

    المؤلفون: Francke, Stephan1, Mamidi, Rao N. V. S.1, Solanki, Bhavna1, Scheers, Ellen2, Jadwin, Andrew1, Favis, Reyna1, Devineni, Damayanthi1

    المصدر: Journal of Clinical Pharmacology. Sep2015, Vol. 55 Issue 9, p1061-1072. 12p.

    مصطلحات موضوعية: *GLUCURONIDATION, *GLUCURONOSYLTRANSFERASE, *CANAGLIFLOZIN, *DRUG metabolism, *URIDINE diphosphate, *MICROSOMES, *LIVER, *ALLELES, *INTESTINES, *KIDNEYS, *NUCLEOTIDES, *PHARMACOGENOMICS, *TRANSFERASES, *IN vitro studies, *IN vivo studies


    أضف إلى المفضلة
  3. 3
    دورية أكاديمية
    Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?

    المؤلفون: Mamidi, Rao N. V. S.1 smamidi1@its.jnj.com, Weng, Steve2, Stellar, Susan1, Wang, Charles1, Ning Yu1, Huang, Tony3,4, Tonelli, Alfred P.1, Kelley, Michael F.1, Angiuoli, Anthony5, Man-Cheong Fung5

    المصدر: Cancer Chemotherapy & Pharmacology. Nov2010, Vol. 66 Issue 6, p1173-1184. 12p. 5 Charts, 4 Graphs.

    مصطلحات موضوعية: *PHARMACOKINETICS, *DOXORUBICIN, *THERAPEUTIC equivalency in drugs, *TOXICITY testing, *MEDICAL research


    أضف إلى المفضلة
  4. 4
    دورية أكاديمية
    Prediction of the drug–drug interaction potential of the α1‐acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib.

    المؤلفون: De Zwart, Loeckie1 (AUTHOR), Snoeys, Jan1 (AUTHOR), Jacobs, Frank1 (AUTHOR), Li, Lilian Y.2 (AUTHOR), Poggesi, Italo3 (AUTHOR), Verboven, Peter1 (AUTHOR), Goris, Ivo1 (AUTHOR), Scheers, Ellen1 (AUTHOR), Wynant, Inneke1 (AUTHOR), Monshouwer, Mario1 (AUTHOR), Mamidi, Rao N. V. S.4 (AUTHOR) smamidi1@its.jnj.com

    المصدر: CPT: Pharmacometrics & Systems Pharmacology. Sep2021, Vol. 10 Issue 9, p1107-1118. 12p.

    مصطلحات موضوعية: *DRUG interactions, *FIBROBLAST growth factor receptors, *FIBROBLAST growth factors, *CYTOCHROME P-450, *CYTOCHROME P-450 CYP3A, *DRUGS

    النص الكامل

    أضف إلى المفضلة
  5. 5
    دورية أكاديمية
    Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE).

    المؤلفون: Saad, Fred1 (AUTHOR) fred.saad@umontreal.ca, Chi, Kim N.2 (AUTHOR), Shore, Neal D.3 (AUTHOR), Graff, Julie N.4 (AUTHOR), Posadas, Edwin M.5 (AUTHOR), Lattouf, Jean-Baptiste1 (AUTHOR), Espina, Byron M.6 (AUTHOR), Zhu, Eugene7 (AUTHOR), Yu, Alex8 (AUTHOR), Hazra, Anasuya8 (AUTHOR), De Meulder, Marc9 (AUTHOR), Mamidi, Rao N. V. S.7 (AUTHOR), Bradic, Branislav7 (AUTHOR), Francis, Peter10 (AUTHOR), Hayreh, Vinny6 (AUTHOR), Rezazadeh Kalebasty, Arash11 (AUTHOR)

    المصدر: Cancer Chemotherapy & Pharmacology. Jul2021, Vol. 88 Issue 1, p25-37. 13p.

    مصطلحات موضوعية: *CASTRATION-resistant prostate cancer, *ABIRATERONE acetate, *PHARMACOKINETICS, *THERAPEUTIC use of antineoplastic agents, *STEROID drugs, *RESEARCH, *CLINICAL trials, *HETEROCYCLIC compounds, *RESEARCH methodology, *CELL receptors, *HYDANTOIN, *ANTINEOPLASTIC agents, *MEDICAL cooperation, *EVALUATION research, *PIPERIDINE, *COMPARATIVE studies, *PREDNISONE, *PROSTATE tumors


    أضف إلى المفضلة
  6. 6
    دورية أكاديمية
    Metabolism and disposition in rats, dogs, and humans of erdafitinib, an orally administered potent pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor.

    المؤلفون: Scheers, Ellen1 (AUTHOR), Borgmans, Carine1 (AUTHOR), Keung, Chi2 (AUTHOR), Bohets, Hilde3 (AUTHOR), Wynant, Inneke1 (AUTHOR), Poggesi, Italo4 (AUTHOR), Cuyckens, Filip1 (AUTHOR), Leclercq, Laurent1 (AUTHOR), Mamidi, Rao N. V. S.5 (AUTHOR)

    المصدر: Xenobiotica. Feb2021, Vol. 51 Issue 2, p177-193. 17p.

    مصطلحات موضوعية: *PROTEIN-tyrosine kinase inhibitors, *PSYCHONEUROIMMUNOLOGY, *BILE, *DOGS, *RATS, *METABOLISM, *HUMAN beings


    أضف إلى المفضلة
  7. 7
    دورية أكاديمية
    Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants.

    المؤلفون: Devineni, Damayanthi1, Manitpisitkul, Prasarn1, Murphy, Joseph1, Skee, Donna1, Wajs, Ewa2, Mamidi, Rao N. V. S.1, Tian, Hong1, Vandebosch, An2, Wang, Shean-Sheng1, Verhaeghe, Tom2, Stieltjes, Hans2, Usiskin, Keith1

    المصدر: Clinical Pharmacology in Drug Development. May2015, Vol. 4 Issue 3, p226-236. 11p.

    مصطلحات موضوعية: *DRUG interactions, *CANAGLIFLOZIN, *PHARMACOKINETICS, *METFORMIN, *SIMVASTATIN, *HYPOGLYCEMIC agents, *TYPE 2 diabetes treatment


    أضف إلى المفضلة
  8. 8
    دورية أكاديمية
    Successful Integration of Nonclinical and Clinical Findings in Interpreting the Clinical Relevance of Rodent Neoplasia with a New Chemical Entity.

    المؤلفون: Johnson, Mark D.1, Louden, Calvert2, De Jonghe, Sandra3, Ways, Kirk3, Mamidi, Rao N. V. S.1, Proctor, James1

    المصدر: Toxicologic Pathology. Jan2015, Vol. 43 Issue 1, p48-56. 9p.

    مصطلحات موضوعية: *SODIUM-glucose cotransporters, *CANAGLIFLOZIN, *CARCINOGENICITY, *ANIMAL models in research, *TYPE 2 diabetes treatment, *PHEOCHROMOCYTOMA, *LEYDIG cell tumors

    النص الكامل

    أضف إلى المفضلة
  9. 9
    دورية أكاديمية
    Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14C-bortezomib.

    المؤلفون: Hemeryck, Alex1 ahemeryc@prdbe.jnj.com, Geerts, Rita1, Monbaliu, Johan1, Hassler, Stephan2, Verhaeghe, Tom1, Diels, Luc1, Verluyten, Willy1, van Beijsterveldt, Ludy1, Mamidi, Rao N. V. S.3, Janssen, Cor1, De Coster, Roland1

    المصدر: Cancer Chemotherapy & Pharmacology. Dec2007, Vol. 60 Issue 6, p777-787. 11p. 1 Black and White Photograph, 1 Diagram, 4 Charts, 2 Graphs.

    مصطلحات موضوعية: *TISSUES, *HISTOLOGY, *BLOOD plasma, *INTRAVENOUS therapy, *NERVOUS system, *BILIARY tract, *IMMUNE system


    أضف إلى المفضلة
  10. 10
    دورية أكاديمية
    Synthesis and biological activity of novel pyrimidinone containing thiazolidinedione derivatives

    المؤلفون: Madhavan, Gurram R.1 madhavangr@drreddys.com, Chakrabarti, Ranjan2 ranjanchakrabarti@drreddys.com, Vikramadithyan, Reeba K.2, Mamidi, Rao N. V. S.2, Balraju, V.1, Rajesh, B.M.1, Misra, Parimal2, Kumar, Sunil K. B.2, Lohray, Braj B.1, Lohray, Vidya B.1, Rajagopalan, Ramanujam2

    المصدر: Bioorganic & Medicinal Chemistry. Aug2002, Vol. 10 Issue 8, p2671. 10p.

    مصطلحات موضوعية: *PYRIMIDINES, *LABORATORY mice, *HYPERGLYCEMIA


    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث